Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir in pediatric post-transplant CMV infection
2023-508988-73-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of maribavir in cytomegalovirus disease (CMV), sponsored by Takeda. Primary endpoints: Maribavir pharmacokinetics at steady state and Safety and tolerability of maribavir. Planned start Apr 2024; status: authorised.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2023-508988-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508988-73-00.